ReviewClinical and experimental medicine2026
Multi-omics data integration using time-to event endpoint and supervised Cox penalized regression: a comprehensive review.
Review in Clinical and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The integration of multi-omics data, encompassing genomics, transcriptomics, epigenomics, and proteomics, has revolutionized medical research by enabling a more comprehensive understanding of complex diseases like cancer. Multi-omics prognostic models facilitate improved patient stratification through personalized prognostication. However, the high dimensionality, heterogeneity, and correlations between omics layers pose significant challenges for predictive modelling building, particularly in time-to-event analyses. This review synthesizes current methodologies for variable selection and regularization in high-dimensional settings, focusing on their application to survival outcomes. We explore global penalty approaches, such as LASSO, Ridge, and Elastic Net, which apply uniform penalties to control model complexity and improve generalizability. Parallel regression methods, which independently analyse different omics layers before integrating results, offering robustness but potentially missing critical correlation. Group regularization techniques, including Group LASSO and OSCAR regression, address multicollinearity by clustering correlated predictors, enhancing interpretability in high-dimensional datasets. Hierarchical regression models, such as Priority LASSO and IPF-LASSO, leverage prior knowledge of omics relationships to improve integration and interpretability but may overlook platform interactions. Kernel-based methods like KEN-COX are also examined for their ability to handle nonlinear relationships and reduce dimensionality. Each method presents unique trade-offs between interpretability, computational efficiency, and predictive performance. This review highlights the need for tailored approaches that balance these factors, emphasizing the importance of model transparency and clinical applicability. Future research should focus on refining these techniques to better capture the complex interplay of omics data in disease progression and survival outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.